Monday, April 8, 2013
Pharma Ltd. emerged last year from a shuttered Pfizer
Inc. R&D site in Sandwich, U.K., with a quartet of allergy and
inflammation assets that otherwise would have been shelved and forgotten. The
biotech's lead program for steroid-refractory atopic dermatitis could avoid
toxicity issues that sidelined a competing program and could be first in class
for the indication.
Last November, Ziarco
in-licensed exclusive, worldwide rights to the assets. Pfizer received an
equity stake and is eligible for milestones, plus royalties. Ziarco co-founder,
President and CEO Mike Yeadon was VP and CSO of Pfizer's allergy and
respiratory research unit at Sandwich.